According to the company, the VIRGO trial evaluated the safety and efficacy of the investigational twice-daily administration of pilocarpine HCl ophthalmic solution 1.25% in adults with presbyopia. The trial met its primary efficacy endpoint, the company noted.
April is Presbyopia Awareness Month. Brieann K. Adair, OD, of NYU Langone Health, speaks with Ophthalmology Times’ Sheryl Stevenson about the importance of Presbyopia awareness, treatment options and more.
The company has dosed the first patients in a Phase 3 trial evaluating the safety and efficacy of Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia.
Study investigators compared 2 novel lens designs using data obtained from 19 investigational sites in Australia, Canada, Spain, and the UK
Presbyopia-correcting drops represent a whole new product category—one with a lot of upsides for clinicians who want to help their patients see well at all distances.
The future of this age-related condition is bright and in focus.
The approach seems to provide high levels of spectacle independence and patients' satisfaction, with limited complications associated.
Spectacle independence is not the main factor that determines patients’ lens selections, according to study investigators.
The approval will allow LensGen to move forward with the IDE pivotal trial with the ultimate goal of seeking premarket approval in the United States.
This model can restore visual function and provide good intermediate and near vision in both photopic and mesopic conditions.
The VIVID study focuses on three novel topical ophthalmic formulations under investigation for the treatment of presbyopia
Lens combines diffractive multifocal and extended depth-of-focus properties.
Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia.
Demographics show high demand for solutions beyond eyeglasses.
